guanfacine has been researched along with Cognitive Decline in 2 studies
Guanfacine: A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barcelos, NM | 1 |
| Van Ness, PH | 1 |
| Wagner, AF | 1 |
| MacAvoy, MG | 1 |
| Mecca, AP | 1 |
| Anderson, GM | 1 |
| Trentalange, M | 1 |
| Hawkins, KA | 1 |
| Sano, M | 1 |
| Arnsten, AFT | 1 |
| van Dyck, CH | 1 |
| Bilder, RM | 1 |
| Loo, SK | 1 |
| McGough, JJ | 1 |
| Whelan, F | 1 |
| Hellemann, G | 1 |
| Sugar, C | 1 |
| Del'Homme, M | 1 |
| Sturm, A | 1 |
| Cowen, J | 1 |
| Hanada, G | 1 |
| McCracken, JT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Eight-Week, Randomized, Double-Blind Comparison of Guanfacine, Focalin XR, and the Combination, With a Twelve Month Open-Label Extension for the Treatment of ADHD in Pediatric Subjects Aged 7 to 14 Years[NCT00429273] | Phase 4 | 212 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The primary clinical efficacy variable for treatment was the ADHD-RS-IV (Attention-Deficit/Hyperactivity Disorder Rating Scale) Total Score and two sub-scales (Inattentive and Hyperactive-Impulsive ).~The rating scale has 18 questions with answer options: None (0), Mild (1), Moderate (2) and Severe (3). Min 0; max 3.~Scores are obtained by summing each item; The higher the score, the worse the outcome.~Total score range: 0-54 Total Inattentive score range: 0-27 Total Hyperactive/Impulsive score range: 0-27" (NCT00429273)
Timeframe: Measured at baseline Week 4 and Week 8
| Intervention | units on a scale (Least Squares Mean) | ||
|---|---|---|---|
| Total ADHD-RS Score | Inattentive Subscale | Hyperactive Impulsive Subscale | |
| Estimated Difference Between DMPH and Placebo | -7.99 | -4.10 | -4.0 |
| Estimated Difference Between Guan and Placebo | -7.77 | -4.14 | -3.73 |
| Estimated Difference Between Placebo and Combo | -10.66 | -5.89 | -5.10 |
2 trials available for guanfacine and Cognitive Decline
| Article | Year |
|---|---|
Guanfacine treatment for prefrontal cognitive dysfunction in older participants: a randomized clinical trial.
Topics: Adrenergic alpha-2 Receptor Agonists; Age Factors; Aged; Aged, 80 and over; Cognitive Dysfunction; D | 2018 |
Cognitive Effects of Stimulant, Guanfacine, and Combined Treatment in Child and Adolescent Attention-Deficit/Hyperactivity Disorder.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Attention Deficit Disorder with Hyperactivity; Cen | 2016 |